Genentech Projects Limited Impact From FOBs; Roche Says Outlook Less Rosy
This article was originally published in The Pink Sheet Daily
Executive Summary
Disclosures in tender offer documents could feed into legislative debate on biosimilars.
You may also be interested in...
Fate Of FOB Legislation Under New Congress Is Front And Center At BIO CEO Conference
BIO may be back to the drawing board in its lobbying push for lengthy exclusivity periods in follow-on biologics legislation, policy experts say.
Merger Gamesmanship: Genentech Had Countered First Roche Bid With 26% Higher Asking Price
Roche SEC filing outlines several “key areas of disagreement,” including assumptions on annual product price increases and pipeline productivity.
Roche’s High-Stakes Gambit For Genentech
In a risky attempt to bring Genentech to the negotiating table, Roche appeals directly to shareholders with a lower offer for the flagship biotechnology company.